Gastric inhibitory polypeptide activates MAP kinase through the wortmannin-sensitive and -insensitive pathways

Area of Science:

• Cellular signaling
• Molecular endocrinology
• Signal transduction

Background:

• Gastric inhibitory polypeptide (GIP) is a key incretin hormone involved in glucose homeostasis.
• GIP receptor signaling pathways are crucial for understanding its physiological effects.
• MAP kinase (Mitogen-Activated Protein kinase) pathways are central to cellular responses.

Purpose of the Study:

• To investigate the signal transduction pathways activated by the human GIP receptor.
• To elucidate the role of MAP kinase activation in GIP receptor signaling.
• To determine the involvement of phosphatidylinositol 3-kinase (PI3-kinase) and cyclic AMP (cAMP) in GIP-mediated signaling.

Main Methods:

• Stable expression of the human GIP receptor in Chinese Hamster Ovary (CHO) cells.
• Stimulation with GIP and measurement of MAP kinase activity.
• Time-course and dose-response analyses of GIP-induced signaling.
• Pharmacological inhibition using wortmannin (PI3-kinase inhibitor) and forskolin (cAMP enhancer).

Main Results:

• GIP significantly increased MAP kinase activity in a dose- and time-dependent manner.
• GIP-induced MAP kinase activation was partially inhibited by wortmannin, indicating dual pathways.
• Elevated intracellular cAMP levels (induced by forskolin) inhibited GIP-induced MAP kinase activation via a wortmannin-sensitive pathway, but not the wortmannin-insensitive pathway.
• Findings suggest GIP activates MAP kinase via wortmannin-sensitive (at/above Raf-1) and -insensitive (below Raf-1) pathways.

Conclusions:

• The human GIP receptor activates the MAP kinase cascade through at least two distinct signal transduction pathways.
• These pathways differ in their sensitivity to wortmannin and are modulated by intracellular cAMP levels.
• Understanding these pathways provides insight into the complex cellular actions of GIP.